Company Encyclopedia
View More
name
Sinopharm Accord
000028.SZ
China National Accord Medicines Corporation Ltd. engages in the retail and distribution of pharmaceutical products in China and internationally. It offers drugs, medical equipment, cargo transportation, warehousing, loading and unloading, glass instruments, cosmetics, sales of daily necessities, other business services, and other professional consulting services; agent services; and house leasing services. The company is also involved in the import and export of proprietary Chinese medicines, chemical preparations, antibiotics, biochemical drugs, biological preparations, diagnostic drugs, therapeutic and diagnostic biological products, packaged foods, chemical products, house supplies, and self-operated technologies.
406.00 B
000028.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Health Care DistributorsIndustry
Industry Ranking7/25
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE2.92%C
    • Profit Margin0.73%C
    • Gross Margin10.18%E
  • Growth ScoreD
    • Revenue YoY-3.08%D
    • Net Profit YoY-63.80%D
    • Total Assets YoY-2.74%D
    • Net Assets YoY-0.50%D
  • Cash ScoreB
    • Cash Flow Margin13675.48%A
    • OCF YoY-3.08%D
  • Operating ScoreA
    • Turnover1.42A
  • Debt ScoreD
    • Gearing Ratio57.38%D

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    SINOPHARM's subsidiary Sinopharm Accord earned 957 million RMB in the first three quarters, a decline of 10.2%

    SINOPHARM announced that its subsidiary Sinopharm Accord reported a revenue of RMB 55.124 billion for the first three quarters, a year-on-year decrease of 2.4%. The net profit attributable to shareholders was RMB 957 million, down 10.2%, with earnings per share of RMB 1.72

    AASTOCKS·
    HK
    01099
    +0.49%
    SZ
    000028
    +0.04%
    AASTOCKS·
    HK
    01099
    +0.49%
    SZ
    000028
    +0.04%

    SINOPHARM: Sinopharm Accord's net profit attributable to shareholders for the first three quarters was 957 million yuan, a year-on-year decrease of 10.18%

    SINOPHARM announced the performance of Sinopharm Accord for the first three quarters of 2025, with operating revenue of 55.124 billion yuan, a year-on-year decrease of 2.38%; net profit attributable to the parent company of 959 million yuan, a year-on-year decrease of 10.18%; and basic earnings per share of 1.72 yuan. In the third quarter of 2025, operating revenue was 18.328 billion yuan, a year-on-year decrease of 1.89%; net profit attributable to the parent company was 291 million yuan, a year-on-year decrease of 9.58%

    Zhitong·
    SZ
    000028
    +0.04%
    HK
    01099
    +0.49%
    Zhitong·
    SZ
    000028
    +0.04%
    HK
    01099
    +0.49%

    Sinopharm Subsidiary Sinopharm Accord Reports Q3 Revenue Decline

    Sinopharm Group Co. Ltd. reported that its subsidiary, China National Accord Medicines Corporation Ltd. (Sinopharm Accord), experienced a revenue decline of 1.89% year-on-year, totaling RMB 18.33 billion for Q3 2025. However, total assets increased by 6.31% to RMB 50.56 billion, and equity attributable to shareholders rose by 4.30% to RMB 18.43 billion compared to the previous year.

    Reuters·
    SZ
    200028
    0.00%
    HK
    01099
    +0.49%
    SZ
    000028
    +0.04%
    Reuters·
    SZ
    200028
    0.00%
    HK
    01099
    +0.49%
    SZ
    000028
    +0.04%

    Sinopharm Accord's net profit attributable to shareholders for the first three quarters was 957 million yuan, a year-on-year decrease of 10.18%

    Sinopharm Accord's performance report for the first three quarters of 2025 shows an operating income of 55.124 billion yuan, a year-on-year decrease of 2.38%; net profit attributable to the parent company is 0.957 billion yuan, a year-on-year decrease of 10.18%. The distribution segment's revenue is 40.594 billion yuan, with a net profit of 0.723 billion yuan, representing decreases of 0.59% and 7.32%, respectively. The retail segment's revenue is 15.226 billion yuan, with a net profit of 0.013 billion yuan, a year-on-year increase of 133.91%

    Zhitong·
    SZ
    000028
    +0.04%
    Zhitong·
    SZ
    000028
    +0.04%

    Sinopharm Accord Reports Decline in Revenue and Profits for H1 2025

    Sinopharm Group Co. Ltd. reported a decline in revenue and profits for its subsidiary, China National Accord Medicines Corporation Ltd. (Sinopharm Accord) for H1 2025. Revenue fell by 2.62% to 36.8 billion yuan, while net profit dropped by 10.43% to 665.9 million yuan. Operating cash flow decreased by 98.38%. However, total assets increased by 6.04% to over 50.4 billion yuan, and net assets attributable to shareholders rose by 2.64%.

    Reuters·
    SZ
    200028
    0.00%
    HK
    01099
    +0.49%
    SZ
    000028
    +0.04%
    Reuters·
    SZ
    200028
    0.00%
    HK
    01099
    +0.49%
    SZ
    000028
    +0.04%
    © 2025 Longbridge｜Disclaimer